Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma

Immunotherapy

Volumn 4, Issue 10, 2012, Pages 1043-1051

  Arnason, Jon ^a   Avigan, David ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CTLA 4; dendritic cell; immunotherapy; lenalidomide; multiple myeloma; PD 1; vaccine

Indexed keywords

CD40 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; PROGRAMMED DEATH 1 RECEPTOR;

ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER MORTALITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL THERAPY; CELLULAR IMMUNOTHERAPY; DENDRITIC CELL; EVENT FREE SURVIVAL; GENE OVEREXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MORBIDITY; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; DENDRITIC CELLS; HUMANS; MULTIPLE MYELOMA; T-LYMPHOCYTES, REGULATORY; TISSUE THERAPY; TRANSPLANTATION, HOMOLOGOUS; VACCINATION;

EID: 84869200003     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.118     Document Type: Review

References (94)

1. Palumbo A, Anderson K. Multiple myeloma. N. Engl. J. Med. 364(11), 1046-1060 (2011).
2. Bird JM, Russell NH, Samson D. Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant. 12(6), 651-654 (1993).
3. Seiden MV, Schlossman R, Andersen J et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Leuk. Lymphoma 17(1-2), 87-93 (1995).
4. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome. Blood 88(7), 2787-2793 (1996).
5. Russell NH, Miflin G, Stainer C et al. Allogeneic bone marrow transplant for multiple myeloma. Blood 89(7), 2610-2611 (1997).
6. Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J. Clin. Oncol. 13(6), 1312-1322 (1995).
7. Kuruvilla J, Shepherd JD, Sutherland HJ et al. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant. 13(8), 925-931 (2007).
8. Crawley C, Lalancette M, Szydlo R et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 105(11), 4532-4539 (2005).
9. Mohty M, Kuentz M, Michallet M et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 100(9), 3128-3134 (2002).
10. Bellucci R, Alyea EP, Weller E et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood 99(12), 4610-4617 (2002).
11. Kroger N, Kruger W, Renges H et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br. J. Haematol. 112(2), 421-423 (2001).
12. Badros A, Barlogie B, Morris C et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 97(9), 2574-2579 (2001).
13. Orsini E, Alyea EP, Schlossman R et al. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant. 25(6), 623-632 (2000).
14. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 87(3), 1196-1198 (1996).
15. Lokhorst HM, Wu K, Verdonck LF et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 103(11), 4362-4364 (2004).
16. Bruno B, Rotta M, Patriarca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N. Engl. J. Med. 356(11), 1110-1120 (2007).
17. Garban F, Attal M, Michallet M et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107(9), 3474-3480 (2006).
18. Rotta M, Storer BE, Sahebi F et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 113(14), 3383-3391 (2009).
19. Kumar S, Zhang MJ, Li P et al. Trends in allogeneic stem cell transplantation for multiple myeloma: A CIBMTR analysis. Blood 118(7), 1979-1988 (2011).
20. Takahashi T, Makiguchi Y, Hinoda Y et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J. Immunol. 153(5), 2102-2109 (1994).
21. Szmania S, Tricot G, van Rhee F. NY-ESO-1 immunotherapy for multiple myeloma. Leuk. Lymphoma 47(10), 2037-2048 (2006).
22. Hatta Y, Takeuchi J, Saitoh T et al. WT1 expression level and clinical factors in multiple myeloma. J. Biol. Blood Marrow Transplant. 24(4), 595-599 (2005).
23. van Rhee F, Szmania SM, Zhan F et al. NY-ESO-1 is highly expressed in poorprognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 105(10), 3939-3944 (2005).
24. Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood 100(3), 961-965 (2002).
25. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 138(5), 563-579 (2007).
26. Spisek R, Kukreja A, Chen LC et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J. Exp. Med. 204(4), 831-840 (2007).
27. Racanelli V, Leone P, Frassanito MA et al. Alterations in the antigen processingpresenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood 115(6), 1185-1193 (2011).
28. Giannopoulos K, Kaminska W, Hus I, Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br. J. Cancer 106(3), 546-552 (2012).
29. Yang DH, Park JS, Jin CJ et al. The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk. Res. 33(5), 665-670 (2009).
30. Pfeifer S, Schreder M, Bolomsky A et al. Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth. J. Cancer Res. Clin. Oncol. doi:10.1007/s00432-012-1259-2 (2012) (Epub ahead of print).
31. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99(19), 12293-12297 (2002).
32. Rosenblatt J, Glotzbecker B, Mills H et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 34(5), 409-418 (2011).
33. Hallett WH, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol. Blood Marrow Transplant. 17(8), 1133-1145 (2010).
34. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumorspecific transplantation antigens. Proc. Natl Acad. Sci. USA 69(6), 1540-1544 (1972).
35. Houet L, Veelken H. Active immunotherapy of multiple myeloma. Eur. J. Cancer 42(11), 1653-1660 (2006).
36. Zahradova L, Mollova K, Ocadlikova D et al. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results. Neoplasma 59(4), 440-449 (2012).
37. Rollig C, Schmidt C, Bornhauser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J. Immunother. 34(1), 100-106 (2011).
38. Yi Q, Szmania S, Freeman J et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma: Intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br. J. Haematol. 150(5), 554-564 (2010).
39. Lacy MQ, Mandrekar S, Dispenzieri A et al. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am. J. Hematol. 84(12), 799-802 (2009).
40. Curti A, Tosi P, Comoli P et al. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br. J. Haematol. 139(3), 415-424 (2007).
41. Wang S, Hong S, Wezeman M, Qian J, Yang J, Yi Q. Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma. Front. Biosci. 12, 3566-3575 (2007).
42. Bendandi M, Rodriguez-Calvillo M, Inoges S et al. Combined vaccination with idiotypepulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk. Lymphoma 47(1), 29-37 (2006).
43. Reichardt VL, Milazzo C, Brugger W, Einsele H, Kanz L, Brossart P. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica 88(10), 1139-1149 (2003).
44. Titzer S, Christensen O, Manzke O et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects. Br. J. Haematol. 108(4), 805-816 (2000).
45. Cull G, Durrant L, Stainer C, Haynes A, Russell N. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br. J. Haematol. 107(3), 648-655 (1999).
46. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant. 6(6), 621-627 (2000).
47. Hansson L, Abdalla AO, Moshfegh A et al Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin. Cancer Res. 13(5), 1503-1510 (2007).
48. Wen YJ, Ling M, Bailey-Wood R, Lim SH. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin. Cancer Res. 4(4), 957-962 (1998).
49. Lim SH, Bailey-Wood R. Idiotypic proteinpulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer 83(2), 215-222 (1999).
50. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 93(7), 2411-2419 (1999).
51. Qian J, Wang S, Yang J et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin. Cancer Res. 11(24 Pt 1), 8808-8815 (2005).
52. Brossart P, Schneider A, Dill P et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 61(18), 6846-6850 (2001).
53. Lim SH, Wang Z, Chiriva-Internati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 97(5), 1508-1510 (2001).
54. Atanackovic D, Arfsten J, Cao Y et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 109(3), 1103-1112 (2007).
55. Hundemer M, Schmidt S, Condomines M et al. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp. Hematol. 34(4), 486-496 (2006).
56. Pellat-Deceunynck C, Mellerin MP, Labarriere N et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur. J. Immunol. 30(3), 803-809 (2000).
57. Ocadlikova D, Kryukov F, Mollova K et al. Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT-drived nonapeptides or myeloma cell apoptotic bodies. Neoplasma 57(5), 455-464 (2010).
58. Yasukawa M, Fujiwara H, Ochi T et al. Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome. Am. J. Hematol. 84(5), 314-315 (2009).
59. Ochsenreither S, Fusi A, Geikowski A et al. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3beta sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer Immunol. Immunother. 61(3), 313-322 (2012).
60. Kovjazin R, Volovitz I, Kundel Y et al. ImMucin: A novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine 29(29-30), 4676-4686 (2011).
61. Batchu RB, Moreno AM, Szmania SM et al. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res. 65(21), 10041-10049 (2005).
62. Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev. 13(1), 51-64 (1999).
63. Chauhan D, Singh AV, Brahmandam M et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A therapeutic target. Cancer Cell 16(4), 309-323 (2009).
64. Szabolcs P, Moore MA, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J. Immunol. 154(11), 5851-5861 (1995).
65. Lee JJ, Choi BH, Kang HK et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk. Lymphoma 48(10), 2022-2031 (2007).
66. Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101(3), 977-982 (2003).
67. Yang DH, Kim MH, Lee YK et al. Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins. Ann. Hematol. 90(12), 1419-1426 (2011).
68. Yang DH, Kim MH, Hong CY et al. Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Ann. Hematol. 89(8), 795-801 (2010).
69. Rosenblatt J, Kufe D, Avigan D. Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opin. Biol. Ther. 5(5), 703-715 (2005).
70. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3(5), 558-561 (1997).
71. Vasir B, Borges V, Wu Z et al. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br. J. Haematol. 129(5), 687-700 (2005).
72. Hayashi T, Hideshima T, Akiyama M et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 102(4), 1435-1442 (2003).
73. Cohen S, Haimovich J, Hollander N. Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma. J. Immunol. 182(3), 1667-1673 (2009).
74. Raje N, Hideshima T, Davies FE et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br. J. Haematol. 125(3), 343-352 (2004).
75. Gong J, Koido S, Chen D et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 99(7), 2512-2517 (2002).
76. Rosenblatt J, Vasir B, Uhl L et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117(2), 393-402 (2011).
77. Rosenblatt J, Avivi I, Vasir B et al. Dendritic cell tumor fusion vaccination in conjunction with autologous transplantation for multiple myeloma. Blood (ASH Annual Meeting Abstracts) 114, Abstract 783 (2009).
78. Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95(10), 3011-3019 (2000).
79. Koike N, Pilon-Thomas S, Mule JJ. Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J. Immunother. 31(4), 402-412 (2008).
80. Rapoport AP, Stadtmauer EA, Aqui N et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11(11), 1230-1237 (2005).
81. Rapoport AP, Aqui NA, Stadtmauer EA et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 117(3), 788-797 (2011).
82. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012).
83. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224, 166-182 (2008).
84. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
85. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2), 141-151 (1999).
86. Nishimura H, Okazaki T, Tanaka Y et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291(5502), 319-322 (2001).
87. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077), 682-687 (2006).
88. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78(11), 5535-5545 (2004).
89. Rosenblatt J, Glotzbecker B, Mills H et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 34(5), 409-418 (2011).
90. Prutchi-Sagiv S, Golishevsky N, Oster HS et al Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: Could it be beneficial in early disease? Br. J. Haematol. 135(5), 660-672 (2006).
91. Quach H, Ritchie D, Stewart AK et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24(1), 22-32 (2010).
92. Galustian C, Meyer B, Labarthe MC et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother. 58(7), 1033-1045 (2009).
93. Luptakova K, Rosenblatt J, Glotzbecker B et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol. Immunother. doi:10.1007/s00262- 012-1308-3 (2012) (Epub ahead of print).
94. Noonan K, Rudraraju L, Ferguson A et al. Lenalidomide-induced immunomodulation in multiple myeloma: Impact on vaccines and antitumor responses. Clin. Cancer Res. 18(5), 1426-1434 (2012). (Pubitemid 36077915)